💊 दवाएँ A-Z 🧬 लक्ष्य 🛠 उपकरण 📚 मार्गदर्शिकाएँ
सभी दवाएँ दवा वर्ग चिकित्सीय क्षेत्र दुष्प्रभाव
मार्गदर्शिकाएँ शब्दकोश समयरेखा
तुलनाएँ दवाओं की यात्राएँ दवा परिवार
🇺🇸 English 🇮🇳 हिन्दी

Lutetium Oxodotreotide

CHEMBL4302409 Phase 4 अनुमोदित Protein
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

This radioactive therapy treats neuroendocrine tumors by delivering targeted radiation to tumor cells via somatostatin receptors.

चिकित्सीय क्षेत्र

ऑन्कोलॉजी

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

अक्सर पूछे जाने वाले प्रश्न

This radioactive therapy treats neuroendocrine tumors by delivering targeted radiation to tumor cells via somatostatin receptors.

Yes, Lutetium Oxodotreotide is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4302409. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.

चिकित्सा अस्वीकरण

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.